Valeant Pharmaceuticals International (NYSE:VRX)

CAPS Rating: 2 out of 5

A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.

Results 1 - 20 of 65 : 1 2 3 4 Next »

Recs

0
Member Avatar alphacleaning (67.40) Submitted: 4/29/2016 4:02:32 PM : Outperform Start Price: $32.60 VRX Score: +10.15

oversold, should get better from here

Recs

0
Member Avatar colonelbatguano (< 20) Submitted: 4/29/2016 11:45:55 AM : Underperform Start Price: $33.23 VRX Score: -7.39

Has been and will continue to be a house of cards.

Recs

1
Member Avatar nandanphadke (65.57) Submitted: 4/27/2016 1:21:50 AM : Outperform Start Price: $35.82 VRX Score: +1.02

Undervalued

Recs

1
Member Avatar starberryzx (53.43) Submitted: 4/22/2016 4:11:17 PM : Outperform Start Price: $37.30 VRX Score: -3.04

To the moon!!!

Recs

1
Member Avatar TMFBuck (87.77) Submitted: 4/12/2016 10:27:16 AM : Outperform Start Price: $32.27 VRX Score: +10.13

Taking a flyer on this one. I don't know exactly what it's worth but it seems like things have been over done a bit here.

Recs

1
Member Avatar PearlandTX (48.46) Submitted: 3/22/2016 2:54:08 PM : Outperform Start Price: $31.21 VRX Score: +13.98

Expect recovery from current management failures.

Recs

0
Member Avatar Sparticus501 (< 20) Submitted: 3/20/2016 10:24:13 AM : Outperform Start Price: $26.10 VRX Score: +36.10

Even after the turmoil and massive plunge, this company is still a large diversified global business that's light on bureaucracy and with plenty of growth opportunities. The stock deserved to go down from the $200-plus price, but currently this stock is clearly undervalued at anything under $35 a share.

Recs

0
Member Avatar Benjammin87 (61.63) Submitted: 3/18/2016 2:28:55 PM : Outperform Start Price: $27.13 VRX Score: +30.98

A bit speculative, but I think it has long term potential if it can navigate the numerous issues they've had this year between accounting and other scandals, but they still have a pretty strong business. At this price I think it's pretty attractive as long as they get some of the shenanigans sorted out.

Recs

0
Member Avatar john603 (62.41) Submitted: 3/17/2016 10:15:48 AM : Outperform Start Price: $31.40 VRX Score: +12.37

tsif pharma giant turnaround..

Recs

1
Member Avatar chk999 (99.95) Submitted: 3/15/2016 3:55:26 PM : Outperform Start Price: $33.64 VRX Score: +4.41

Oversold

Recs

0
Member Avatar courtprocanada (63.94) Submitted: 3/15/2016 1:26:57 PM : Outperform Start Price: $36.10 VRX Score: -2.95

Ackman

Recs

0
Member Avatar AnsgarJohn (99.20) Submitted: 3/15/2016 6:40:39 AM : Outperform Start Price: $53.50 VRX Score: -35.49

http://www.gurufocus.com/stock/VRX The Outsider. Buy drugs, raise the price, change the distribution model. Adjusted EPS $10 per share? Bill Ackman, Sequoia Fund.

Recs

0
Member Avatar gcaderas (72.60) Submitted: 3/11/2016 7:15:41 AM : Outperform Start Price: $67.10 VRX Score: -49.10

Qtr (12/15) Qtr (03/16) FY (12/15) FY (12/16)
Average Estimate $2.64 $2.66 $10.22 $13.15
Number of Analysts 8 6 6 8
High Estimate $2.88 $3.17 $10.44 $13.70
Low Estimate $2.57 $2.31 $10.13 $12.28
Prior Year $2.59 $2.34 $8.34 $10.22
Growth Rate (Year over Year) 1.79% 13.82% 22.54% 28.64%

Recs

0
Member Avatar TMFJMo (73.81) Submitted: 3/1/2016 1:02:34 PM : Underperform Start Price: $60.47 VRX Score: +45.33

Have a feeling this one gets worse before it gets better. Too many red flags to outperform, debt to equity getting out of control and deals are only going to get tougher to make.

Recs

1
Member Avatar Kenji94 (42.22) Submitted: 1/6/2016 6:51:44 PM : Underperform Start Price: $100.12 VRX Score: +69.80

A gargantuan amount of debt, combined with a decline in revenue won't bode well for VRX.

Recs

0
Member Avatar drmanand (53.02) Submitted: 11/13/2015 11:14:48 PM : Outperform Start Price: $74.49 VRX Score: -53.85

Should be able to come out of the scandal eventually. Might be good entry point.

Recs

0
Member Avatar km00nster (< 20) Submitted: 11/10/2015 11:15:22 AM : Underperform Start Price: $80.04 VRX Score: +54.50

Going to the 60's. CEO selling, everyone selling, I'm shorting. Nasty stuff

Recs

0
Member Avatar roymarshall (25.54) Submitted: 11/5/2015 3:15:30 PM : Underperform Start Price: $77.80 VRX Score: +52.17

R&O massive fraud lawsuits in December. How can anyone invest in this now? If fraud were found. ..shares are worthless.

Recs

0
Member Avatar jpmgator06 (96.70) Submitted: 11/1/2015 3:35:27 PM : Underperform Start Price: $97.16 VRX Score: +62.13

The next Enron

Recs

6
Member Avatar TMFOpie (95.05) Submitted: 10/28/2015 3:05:52 PM : Outperform Start Price: $115.04 VRX Score: -68.06

Not without controversy for sure but considering what's happened over the last couple of months and what they have in assets and potential earnings I think the stock will outperform a rather lukewarm market over the next several years.

Results 1 - 20 of 65 : 1 2 3 4 Next »

Featured Broker Partners